Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors ; volume:119 ; number:3 ; day:19 ; month:1 ; year:2024 ; pages:255-264 ; date:3.2024
International journal of hematology ; 119, Heft 3 (19.1.2024), 255-264, 3.2024
- Urheber
-
Obara, Naoshi
Usuki, Kensuke
Hayashi, Takeshi
Fujii, Masato
Ikezoe, Takayuki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-023-03698-5
- URN
-
urn:nbn:de:101:1-2405102120215.857691510772
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Obara, Naoshi
- Usuki, Kensuke
- Hayashi, Takeshi
- Fujii, Masato
- Ikezoe, Takayuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life
Paroxysmal nocturnal hemoglobinuria: Where we stand
The complement model disease paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal hemoglobinuria and related disorders : molecular aspects of pathogenesis
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life
Paroxysmal nocturnal hemoglobinuria: Where we stand
The complement model disease paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal hemoglobinuria and related disorders : molecular aspects of pathogenesis
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life
Paroxysmal nocturnal hemoglobinuria: Where we stand
The complement model disease paroxysmal nocturnal hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment
Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal hemoglobinuria and related disorders : molecular aspects of pathogenesis
Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients